Form 4: Vaxcyte CFO Andrew Guggenhime Reports Stock Option Exercise and Sale
SEC Form 4 Filing
Andrew Guggenhime, President and CFO of Vaxcyte, Inc., exercised stock options and sold shares on June 18, 2024, according to a Form 4 filing with the SEC.
Summary
- On June 18, 2024, Andrew Guggenhime, the President and CFO of Vaxcyte, Inc., engaged in transactions involving the company's stock.
- Guggenhime exercised a stock option to acquire 8,000 shares at a price of $5.35 per share.
- He then sold 7,652 shares at a weighted-average price of $71.893, with prices ranging from $71.415 to $72.36.
- Additionally, he sold 348 shares at a weighted-average price of $72.556, with prices ranging from $72.48 to $72.60.
- Following these transactions, Guggenhime beneficially owns 96,720 shares of Vaxcyte, Inc.
Sentiment
Score: 5
Explanation: The document is a neutral report of stock transactions. It doesn't convey any explicit positive or negative sentiment about the company's performance or prospects.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the actions of company executives. It's common for executives to exercise stock options and sell shares for personal financial management.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies and their executives.
- The transactions are similar to those seen at other biotech companies where executives receive stock options as part of their compensation and periodically exercise and sell them.
- The use of a 10b5-1 trading plan is a common method to avoid accusations of insider trading, aligning with industry best practices.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the overall effect is likely minimal given the relatively small number of shares involved.
- The sales were conducted under a pre-arranged trading plan, mitigating concerns about insider information influencing the transactions.
Key Dates
| Date | Description |
|---|---|
| 2021-05-01 | 1/4 of the shares subject to the option vested. |
| 2023-06-30 | Rule 10b5-1 trading plan adopted. |
| 2024-05-17 | 1,041 shares acquired under the Issuer's Employee Stock Purchase Plan. |
| 2024-06-07 | Date of Power of Attorney execution. |
| 2024-06-18 | Date of stock option exercise and stock sales. |
| 2024-06-20 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.